AIMS AND BACKGROUND: ocular melanoma tends to metastasize to the liver, sparing for a long time the rest of the organism. Therefore, a regional treatment is especially indicated. METHODS: eight patients with ocular melanoma metastatic to the liver were treated with intra-arterial hepatic carboplatin-based chemotherapy at the dose of 300 mg/m2 once every two weeks at an out-patient clinic. All the patients were submitted to laparotomy with surgical implantation of an arterial port device through the gastroduodenal artery. RESULTS: the overall response rate was 38% with a median survival time of 15 months. The regimen was well tolerated and the principle toxicity was myelosuppression; any instance of hepatic and/or cholangitic damage was reported. CONCLUSIONS: Carboplatin seems suitable for intra-arterial hepatic chemotherapy and active in ocular melanoma metastatic to the liver.
AIMS AND BACKGROUND: ocular melanoma tends to metastasize to the liver, sparing for a long time the rest of the organism. Therefore, a regional treatment is especially indicated. METHODS: eight patients with ocular melanoma metastatic to the liver were treated with intra-arterial hepatic carboplatin-based chemotherapy at the dose of 300 mg/m2 once every two weeks at an out-patient clinic. All the patients were submitted to laparotomy with surgical implantation of an arterial port device through the gastroduodenal artery. RESULTS: the overall response rate was 38% with a median survival time of 15 months. The regimen was well tolerated and the principle toxicity was myelosuppression; any instance of hepatic and/or cholangitic damage was reported. CONCLUSIONS: Carboplatin seems suitable for intra-arterial hepatic chemotherapy and active in ocular melanoma metastatic to the liver.
Authors: Thomas Vogl; Katrin Eichler; Stephan Zangos; Christopher Herzog; Renate Hammerstingl; Jörn Balzer; Ali Gholami Journal: J Cancer Res Clin Oncol Date: 2006-10-05 Impact factor: 4.553
Authors: Matias E Valsecchi; Mizue Terai; David J Eschelman; Carin F Gonsalves; Inna Chervoneva; Jerry A Shields; Carol L Shields; Akira Yamamoto; Kevin L Sullivan; MaryAnn Laudadio; David Berd; Michael J Mastrangelo; Takami Sato Journal: J Vasc Interv Radiol Date: 2015-02-09 Impact factor: 3.464
Authors: Takami Sato; David J Eschelman; Carin F Gonsalves; Mizue Terai; Inna Chervoneva; Peter A McCue; Jerry A Shields; Carol L Shields; Akira Yamamoto; David Berd; Michael J Mastrangelo; Kevin L Sullivan Journal: J Clin Oncol Date: 2008-10-06 Impact factor: 44.544